PL3200783T3 - Leczenie erytromelalgii - Google Patents
Leczenie erytromelalgiiInfo
- Publication number
- PL3200783T3 PL3200783T3 PL15790622T PL15790622T PL3200783T3 PL 3200783 T3 PL3200783 T3 PL 3200783T3 PL 15790622 T PL15790622 T PL 15790622T PL 15790622 T PL15790622 T PL 15790622T PL 3200783 T3 PL3200783 T3 PL 3200783T3
- Authority
- PL
- Poland
- Prior art keywords
- erythromelalgia
- treatment
- erythromelalgia treatment
- Prior art date
Links
- 201000011384 erythromelalgia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417497.3A GB201417497D0 (en) | 2014-10-03 | 2014-10-03 | Novel use |
| EP15790622.3A EP3200783B1 (en) | 2014-10-03 | 2015-10-02 | Erythromelalgia treatment |
| PCT/GB2015/052885 WO2016051194A1 (en) | 2014-10-03 | 2015-10-02 | Erythromelalgia treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3200783T3 true PL3200783T3 (pl) | 2020-01-31 |
Family
ID=51946794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15790622T PL3200783T3 (pl) | 2014-10-03 | 2015-10-02 | Leczenie erytromelalgii |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10231950B2 (pl) |
| EP (1) | EP3200783B1 (pl) |
| CY (1) | CY1122418T1 (pl) |
| DK (1) | DK3200783T3 (pl) |
| ES (1) | ES2751688T3 (pl) |
| GB (1) | GB201417497D0 (pl) |
| HR (1) | HRP20191434T1 (pl) |
| HU (1) | HUE047940T2 (pl) |
| LT (1) | LT3200783T (pl) |
| PL (1) | PL3200783T3 (pl) |
| PT (1) | PT3200783T (pl) |
| RS (1) | RS59479B1 (pl) |
| SI (1) | SI3200783T1 (pl) |
| SM (1) | SMT201900723T1 (pl) |
| WO (1) | WO2016051194A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201417497D0 (en) * | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| SG11201903667XA (en) * | 2016-11-02 | 2019-05-30 | Biogen Inc | Novel dosage regimen |
| JP2021521227A (ja) * | 2018-04-16 | 2021-08-26 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 神経障害性疼痛を処置する方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO870613L (no) | 1986-03-05 | 1987-09-07 | Molecular Diagnostics Inc | Deteksjon av mikroorganismer i en prve inneholdende nukleinsyre. |
| JP2897959B2 (ja) | 1988-05-20 | 1999-05-31 | エフ．ホフマン―ラ ロシュ アクチェンゲゼルシャフト | 固定化された配列特異的プローブ |
| US5118801A (en) | 1988-09-30 | 1992-06-02 | The Public Health Research Institute | Nucleic acid process containing improved molecular switch |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| CA2134552A1 (en) | 1992-04-27 | 1993-11-11 | George D. Sorenson | Detection of gene sequences in biological fluids |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| JP3267300B2 (ja) | 1995-02-13 | 2002-03-18 | ジー．ディー．サール アンド カンパニー | 炎症の治療のための置換イソオキサゾール |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| GEP20032998B (en) | 1996-04-12 | 2003-06-25 | Searle & Co | Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors |
| US5866336A (en) | 1996-07-16 | 1999-02-02 | Oncor, Inc. | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| US6117635A (en) | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| SI0912518T1 (en) | 1996-07-18 | 2003-12-31 | Merck Frosst Canada & Co. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| ATE281458T1 (de) | 1997-09-05 | 2004-11-15 | Glaxo Group Ltd | Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate |
| ATE275148T1 (de) | 1998-11-03 | 2004-09-15 | Glaxo Group Ltd | Pyrazolopyridin derivative als selektive cox-2 inhibitoren |
| US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
| WO2000052008A1 (en) | 1999-02-27 | 2000-09-08 | Glaxo Group Limited | Pyrazolopyridines |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| US8093268B2 (en) * | 2007-01-24 | 2012-01-10 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) |
| US9376429B2 (en) * | 2012-10-15 | 2016-06-28 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
| EP3666274A1 (en) * | 2013-03-15 | 2020-06-17 | Purdue Pharma LP | Carboxamide derivatives and use thereof |
| GB201409851D0 (en) * | 2014-06-03 | 2014-07-16 | Convergence Pharmaceuticals | Diagnostic method |
| GB201417497D0 (en) * | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| KR102412146B1 (ko) * | 2015-02-11 | 2022-06-22 | 주식회사 아이엔테라퓨틱스 | 소디움 채널 차단제 |
-
2014
- 2014-10-03 GB GBGB1417497.3A patent/GB201417497D0/en not_active Ceased
-
2015
- 2015-10-02 SI SI201530856T patent/SI3200783T1/sl unknown
- 2015-10-02 ES ES15790622T patent/ES2751688T3/es active Active
- 2015-10-02 DK DK15790622.3T patent/DK3200783T3/da active
- 2015-10-02 HR HRP20191434TT patent/HRP20191434T1/hr unknown
- 2015-10-02 WO PCT/GB2015/052885 patent/WO2016051194A1/en not_active Ceased
- 2015-10-02 US US15/516,031 patent/US10231950B2/en active Active
- 2015-10-02 HU HUE15790622A patent/HUE047940T2/hu unknown
- 2015-10-02 EP EP15790622.3A patent/EP3200783B1/en active Active
- 2015-10-02 LT LTEP15790622.3T patent/LT3200783T/lt unknown
- 2015-10-02 SM SM20190723T patent/SMT201900723T1/it unknown
- 2015-10-02 PT PT15790622T patent/PT3200783T/pt unknown
- 2015-10-02 RS RS20190994A patent/RS59479B1/sr unknown
- 2015-10-02 PL PL15790622T patent/PL3200783T3/pl unknown
-
2019
- 2019-01-22 US US16/254,251 patent/US20190388391A1/en not_active Abandoned
- 2019-10-31 CY CY20191101134T patent/CY1122418T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3200783T3 (da) | 2019-08-05 |
| HUE047940T2 (hu) | 2020-05-28 |
| EP3200783A1 (en) | 2017-08-09 |
| ES2751688T3 (es) | 2020-04-01 |
| PT3200783T (pt) | 2019-08-21 |
| HRP20191434T1 (hr) | 2020-10-02 |
| GB201417497D0 (en) | 2014-11-19 |
| WO2016051194A1 (en) | 2016-04-07 |
| US20170304264A1 (en) | 2017-10-26 |
| EP3200783B1 (en) | 2019-07-31 |
| RS59479B1 (sr) | 2019-12-31 |
| SI3200783T1 (sl) | 2020-03-31 |
| CY1122418T1 (el) | 2021-01-27 |
| US10231950B2 (en) | 2019-03-19 |
| SMT201900723T1 (it) | 2020-03-13 |
| US20190388391A1 (en) | 2019-12-26 |
| LT3200783T (lt) | 2019-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3215147T3 (pl) | Związki norketaminy osłabiającej działanie układu nerwowego i sposoby | |
| IL250387A0 (en) | combined treatment | |
| IL248856B (en) | New treatment | |
| GB201405033D0 (en) | Combination therapy | |
| GB201502137D0 (en) | Treatment | |
| GB201608885D0 (en) | Treatment | |
| GB201522243D0 (en) | Treatment | |
| ZA201702522B (en) | Combination therapy | |
| GB201508841D0 (en) | Treatment | |
| GB201503008D0 (en) | Treatment | |
| GB201402179D0 (en) | Surface treatment | |
| SMT201900723T1 (it) | Trattamento dell'eritromelalgia | |
| ZA201608217B (en) | Combination therapy | |
| GB201411027D0 (en) | Treatment | |
| GB201412411D0 (en) | Treatment | |
| GB201617107D0 (en) | Treatment | |
| GB201413317D0 (en) | Atheroscierosis treatment | |
| GB201412410D0 (en) | Treatment | |
| GB201400239D0 (en) | Treatment | |
| GB201400240D0 (en) | Treatment | |
| GB201400235D0 (en) | Treatment | |
| GB201400238D0 (en) | Treatment | |
| GB201400241D0 (en) | Treatment | |
| GB201612260D0 (en) | Treatment | |
| GB201612193D0 (en) | Treatment |